Ativa Medical closes $23mm Series B round to support micro lab development
Diagnostics firm Ativa Medical Corp. raised $23mm through its Series B round, which included $15mm in new equity and...
Venture Funding Deals, October 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.
More from Deals
• By
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
• By
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
• By
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
More from Business
• By
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
• By
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
• By
Multi-blockbuster falls short in a giant cell arteritis study.